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The present thesis has outlined investigation of lung metastasis activation after lymph node resection and prophylactic 
treatment using a lymphatic drug delivery system; tumor cells in the lung metastasis were activated after removal of 
tumor-free and tumor-bearing lymph node and preventive treatment for downstream lymph node was achieved 
anticancer drug injection into its upstream lymph node (SLN).  
In Chapter 1, preclinical models of lymph node (LN) metastasis are described, that have been developed using a mice 
that have LNs equivalent in size to those of humans, and a new metastatic theory called “LN-mediated hematogenous 
metastasis” has been proposed based in this model. It is clear that preclinical models of LN metastasis are indispensable 
in aiding our understanding of the mechanisms involved in tumor cell trafficking and will play a fundamental role in the 
development of new techniques to diagnose and treat LN metastasis. 
Chapter 2 describes how the resection of tumor-bearing and non-tumor-bearing LNs affects distant metastases in 
MXH10/Mo/lpr mice. Luciferase-expressing tumor cells were administered intravenously and/or intranodally into the right 
subiliac LN (SiLN) to create a mouse model of lung metastasis. Luciferase imaging revealed that tumor cells in the lung 
were activated after resection of the SiLN, irrespective of whether the SiLN contained tumor cells hence no luciferase 
activity was detected in the lungs of mice that did not undergo LN resection (excluding those inoculated intravenously with 
tumor cells). These results indicate that resection of a LN can activate distant metastases regardless of whether the LN 
contains tumor cells. The underlying mechanisms of tumor cell activation in the lung after removal of a LN remain unclear. 
Thus, it will be important to develop an improved diagnostic method that can detect cancer at an early stage to help limit its 
progression. 
In Chapter 3, results are described regarding how lung metastasis might be induced by the resection of a tumor-bearing 
LN, with the aim of analyzing vascular structural changes in the lung in the presence and absence of tumor cells in 
MXH10/Mo/lpr mice. This chapter describes how tumor cells and metastatic foci impede the effects of systemic 
chemotherapy, which relies on the enhanced permeability and retention effect, and influence the vascularization of the 
lung. Moreover, growth of tumor masses were observed in the lung arteries; therefore an investigation of blood vessel 
structure in the metastatic lung could potentially be used to facilitate the design of new techniques for the diagnosis and 
systemic circulation-independent treatment of lung metastasis. 
Chapter 4 focuses on the osmotic pressure of the anticancer drug solution, with the aim of establishing a suitable range 
of osmotic pressures that improves retention of the anticancer drug in LNs. Treating the sentinel LN (SLN) using a 
lymphatic drug delivery system, which administers anticancer agents at optimal osmotic pressures, is a novel therapy for 
metastatic LNs at the early stage (i.e. false-negative N0 LNs). As with systemic administration, intranodal injection of a 
high concentration of epirubicin within a short period resulted in the drug being retained in the false-N0 SLN. Overall, these 
findings suggest that a low concentration of an anticancer drug with an osmotic pressure of 1600 – 2335 kPa will provide 
an alternative approach for the efficient treatment of metastasis.  
In Chapter 5 conclusions are drawn on the various roles of the lymphatic system, cancer cell dissemination and cancer 
metastasis. It is speculated that tumor-positive SLN biopsy (SLNB) is a risk factor for the promotion of cancer spread, and 
that a lymphatic drug delivery system could be a new treatment strategy for metastasis. I hope this thesis will contribute 
that cancer research will advance at speeds beyond our expectations, releasing many patients from the fear of cancer. 
 
